Drawing for SEKORIE

USPTO serial 88607443

SEKORIE

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
โ€”
Examiner
MARTIN, CHRISTINE C
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SEKORIE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Cheryl L. Foytlin

Cheryl L. Foytlin JOHNSON & JOHNSONONE JOHNSON & JOHNSON PLAZANEW BRUNSWICK, NJ 08933UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, ophthalmic diseases, respiratory diseases, digital ulcers, and cerebrovascular diseases; vaccines; anxiolytics; anti-allergics; anti-infectives; excluding pharmaceutical preparations for the treatment of oncological diseases and disordersACTIVEโ€”

Related trademarks

CopyMark links this record to cited ยง2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Sep 11, 2023MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 11, 2023ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Feb 25, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILEDโ€”
Feb 24, 2023EX5GSOU EXTENSION 5 GRANTEDโ€”
Feb 24, 2023AITUCASE ASSIGNED TO INTENT TO USE PARALEGALโ€”
Feb 7, 2023EXT5SOU EXTENSION 5 FILEDโ€”
Feb 7, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 2, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILEDโ€”
Jul 29, 2022EX4GSOU EXTENSION 4 GRANTEDโ€”
Jul 29, 2022EXT4SOU EXTENSION 4 FILEDโ€”
Jul 29, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 2, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILEDโ€”
Feb 1, 2022DOCKASSIGNED TO EXAMINERโ€”
Jan 31, 2022EX3GSOU EXTENSION 3 GRANTEDโ€”
Jan 31, 2022EXT3SOU EXTENSION 3 FILEDโ€”
Jan 31, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 29, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILEDโ€”
Jul 27, 2021EX2GSOU EXTENSION 2 GRANTEDโ€”
Jul 27, 2021EXT2SOU EXTENSION 2 FILEDโ€”
Jul 27, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 6, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILEDโ€”
Nov 4, 2020EX1GSOU EXTENSION 1 GRANTEDโ€”
Nov 4, 2020EXT1SOU EXTENSION 1 FILEDโ€”
Nov 4, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 11, 2020NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline โ€” usually six months from the notice date.
Jun 26, 2020CHPBPOST PUBLICATION AMENDMENT - ENTEREDโ€”
Jun 23, 2020APETASSIGNED TO PETITION STAFFโ€”
Jun 18, 2020ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATEDโ€”
May 27, 2020EPPATEAS POST PUBLICATION AMENDMENT RECEIVEDโ€”
Jan 2, 2020ETOFEXTENSION OF TIME TO OPPOSE RECEIVEDโ€”
Dec 10, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILEDโ€”
Dec 10, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 20, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILEDโ€”
Nov 4, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTERโ€”
Nov 1, 2019DOCKASSIGNED TO EXAMINERโ€”
Sep 18, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTEREDโ€”
Sep 10, 2019NWAPNEW APPLICATION ENTEREDโ€”

Frequently asked questions

Related guidance